1.  Baker GB, Wong JT, Yeung JM, Coutts RT. Effects of the antidepressant phenelzine on brain levels of gamma-aminobutyric acid (GABA). J Affect Disord 1991;21:207-211.

 2.  Bakish D, Bradwejn J, Nair N, McClure J, Remick R, Bulger L. A comparison of moclobemide, amitriptyline and placebo in depression: a Canadian multicentre study. Psychopharmacology 1992;106 Suppl:S98-S101.

 3.  Bakish D, Saxena BM, Bowen R, D'Souza J. Reversible monoamine oxidase-A inhibitors in panic disorder. Clin Neuropharmacol 1993;16 (Suppl 2):S77-S82.

 4.  Bergstrom M, Muhr C, Jossan S, Lilja A, Nyberg G, Langstrom B. Differentiation of pituitary adenoma and meningioma: visualization with positron emission tomography and [11C]-L-deprenyl. Neurosurg 1992;30:855-861.

 5.  Berlin I, Said S, Spreux-Varoquaux O, et al. A reversible monoamine oxidase A inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy, dependent smokers. Clin Pharmacol Ther 1995;58:444-452.

 6.  Berlin I, Said S, Spreux-Varoquaux O, Olivares R, Launay JM, Puech AJ. Monoamine oxidase A and B activities in heavy smokers. Biol Psychiatry 1995;38:756-761.

 7.  Bieck PR, Antonin K-H. Tyramine potentiation during treatment with MAOIs. In: S. H. Kennedy, ed. Clinical advances in monoamine oxidase inhibitor therapies. Washington, DC: American Psychiatric Press, Inc., 1994;83-110.

 8.  Birkmayer W, Knoll J, Riederer P, Youdim MB, Hars V, Marton J. Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: A longterm study. J Neural Transm 1985;64:113-127.

 9.  Birkmayer W, Riederer P, Youdim MB, Linauer W. The potentiation of the anti akinetic effect after L-dopa treatment by an inhibitor of MAO-B, Deprenil. J Neural Transm 1975;36:303-326.

10.  Blackwell B. Adverse effects of antidepressant drugs. Part 1: monoamine oxidase inhibitors and tricyclics. Drugs 1981;21:201-219.

11.  Blaschko H. The natural history of amine oxidases. Rev Physiol Biochem Pharmacol 1974;70:83-148.

12. Blier P, De Montigny C, Azzaro AJ. Modification of serotonergic and noradrenergic neurotransmissions by repeated administration of monoamine oxidase inhibitors: electrophysiological studies in the rat central nervous system. J Pharmacol Exp Ther 1986;237:987-994.

13.  Bond PA, Cundall RL. Properties of monoamine oxidase (MAO) in human blood platelets, plasma, lymphocytes and granulocytes. Clin Chim Acta 1977;80:317-326.

14.  Bougerol T, Uchida D, Gachoud JP, et al. Efficacy and tolerability of moclobemide compared with fluvoxamine in depressive disorder (DSM-III): a French/Swiss double-blind trial. Psychopharmacology 1992;106 (suppl):102-108.

15.  Bresnahan DB, Pandey GN, Janicak PG, et al. MAO inhibition and clinical response in depressed patients treated with phenelzine. J Clin Psychiatry 1990;51:47-50.

16.  Brodribb TR, Downey M, Gilbar PJ. Efficacy and adverse effects of moclobemide. Lancet 1994;343:475.

17.  Buchsbaum MS, Coursey RD, Murphy DL. The biochemical high-risk paradigm: behavioral and familial correlates of low platelet monoamine oxidase activity. Science 1976;194:339-341.

18.  Buigues J, Vallejo J. Therapeutic response to phenelzine in patients with panic disorder and agoraphobia with panic attacks. J Clin Psychiatry 1987;48:55-59.

19.  Campi N, Todeschini GP, Scarzella L. Selegiline versus L-acetylcarnitine in the treatment of Alzheimer-type dementia. Clin Ther 1990;12:306-314.

20.  Cases O, Seif I, Grimsby J, et al. Aggressive behavior and altered amounts of brain serotonin and norepinephrine in mice lacking MAOA. Science 1995;268:1763-1766.

21.  Charney DS, Woods SW, Nagy LM, Southwick SM, Krystal JH, Heninger GR. Noradrenergic function in panic disorder. J Clin Psychiatry 1990;51 (Suppl A):5-11.

22.  Chen K, Wu HF, Grimsby J, Shih JC. Cloning of a novel monoamine oxidase cDNA from trout liver. Mol Pharmacol 1994;46:1226-1233.

23.  Chen K, Wu HF, Shih JC. The deduced amino acid sequences of human platelet and frontal cortex monoamine oxidase B are identical. J Neurochem 1993;61:187-190.

24.  Chen K, Wu HF, Shih JC. Influence of C terminus on monoamine oxidase A and B catalytic activity. J Neurochem 1996;66:797-803.

25.  Chen ZY, Denney RM, Breakefield XO. Norrie disease and MAO genes: nearest neighbors. Hum Mol Genet 1995;4 Spec No:1729-1737.

26.  Chiba K, Trevor A, Castagnoli N, Jr. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem Biophys Res Comm 1984;120:574-578.

27.  Chouinard G, Saxena BM, Nair NP, et al. A Canadian multicentre placebo-controlled study of a fixed dose of brofaromine, a reversible selective MAO-A inhibitor, in the treatment of major depression. J Affect Disord 1994;32:105-114.

28.  Cohen RM, Campbell IC, Dauphin M, Tallman JF, Murphy DL. Changes in alpha- and beta-receptor densities in rat brain as a result of treatment with monoamine oxidase inhibiting antidepressants. Neuropharmacology 1982;21:293-298.

29.  Da Prada M, Zurcher G, Wuthrich I, Haefely WE. On tyramine, food, beverages and the reversible MAO inhibitor moclobemide. J Neural Transm Suppl 1988;26:31-56.

30.  Davidson J, Pelton S. Forms of atypical depression and their response to antidepressant drugs. Psychiatry Res 1986;17:87-95.

31.  Davidson JR, Giller EL, Zisook S, Overall JE. An efficacy study of isocarboxazid and placebo in depression, and its relationship to depressive nosology. Arch Gen Psychiatry 1988;45:120-127.

32.  Davidson JR, McLeod MN, Turnbull CD, Miller RD. A comparison of phenelzine and imipramine in depressed inpatients. J Clin Psychiatry 1981;42:395-397.

33.  Devor EJ, Abell CW, Hoffman PL, Tabakoff B, Cloninger CR. Platelet MAO activity in type I and type II alcoholism. Ann NY Acad Sci 1994;708:119-128.

34.  Dexter DT, Carter CJ, Wells FR, et al. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem 1989;52:381-389.

35.  Dollery CT, Brown MJ, Davies DS, Strolin BM. Pressor amines and monoamine oxidase inhibitors. In: Tipton KF, Dostert P, Strolin BM, Benedetti A, eds. Monoamine oxidase and disease. London: Academic Press, 1984;429-441.

36.  Donnez J, Goenen E, Casanas-Roux F, Caprasse J, Ferin J, Thomas K. Monoamine oxidase reactivity in the human fallopian tube. Fertil Steril 1985;43:488-490.

37.  Dostert P. Myth and reality of the classical MAO inhibitors, reasons for seeking a new generation. In: Tipton KF, Dostert P, Strolin BM, Benedetti A, eds. Monoamine oxidase and disease. London: Academic Press, 1984;487-497.

38.  Dostert P. Can our knowledge of monoamine oxidase (MAO) help in the design of better MAO inhibitors? J Neural Transm Suppl 1994;41:269-279.

39.  Dunleavy DL, Oswald I. Phenelzine, mood response, and sleep. Arch Gen Psychiatry 1973;28:353-356.

40.  Edelstein SB, Castiglione CM, Breakfield XO. Monoamine oxidase activity in normal and Lesch-Nyhan fibroblasts. J Neurochem 1978;31:1247-1254.

41.  Falsaperla A, Monici Preti PA, Oliani C. Selegiline versus oxiracetam in patients with Alzheimer-type dementia. Clin Ther 1990;12:376-384.

42.  Flanigan MJ, Hons BS, Shapiro CM. MAOIs and Sleep. In: Kennedy SH, ed. Clinical advances in monoamine oxidase inhibitor therapies. Washington, DC: American Psychiatric Press, Inc., 1994;125-145.

43.  Fowler CJ, Wiberg A, Oreland L, Marcusson J, Winblad B. The effect of age on the activity and molecular properties of human brain monoamine oxidase. J Neural Transm 1980;49:1-20.

44.  Fowler JS, Volkow ND, Logan J, et al. Slow recovery of human brain MAO B after L-deprenyl (selegeline) withdrawal. Synapse 1994;18:86-93.

45.  Fowler JS, Volkow ND, Wang GJ, et al. Inhibition of monoamine oxidase B in the brains of smokers. Nature 1996;379:733-736.

46.  Fowler JS, Volkow ND, Wang GJ, et al. Brain monoamine oxidase A inhibition in cigarette smokers. Proc Natl Acad Sci USA 1996;93:14065-14069.

47.  Frank JB, Kosten TR, Giller EL, Jr, Dan E. A randomized clinical trial of phenelzine and imipramine for posttraumatic stress disorder. Am J Psychiatry 1988;145:1289-1291.

48.  Georgotas A, Friedman E, McCarthy M, et al. Resistant geriatric depressions and therapeutic response to monoamine oxidase inhibitors. Biol Psychiatry 1983;18:195-205.

49.  Georgotas A, McCue RE, Cooper TB. A placebo-controlled comparison of nortriptyline and phenelzine in maintenance therapy of elderly depressed patients. Arch Gen Psychiatry 1989;46:783-786.

50.  Georgotas A, McCue RE, Hapworth W, et al. Comparative efficacy and safety of MAOIs versus TCAs in treating depression in the elderly. Biol Psychiatry 1986;21:1155-1166.

51.  Gleiter CH, Nilsson E, Muhlbauer B, Antonin KH, Bieck PR. Effect of the selective MAO-A inhibitors brofaromine, clorgyline and moclobemide on human platelet MAO-B activity. J Neural Transm Gen Sec 1992;89:129-133.

52.  Goad DL, Davis CM, Liem P, Fuselier CC, McCormack JR, Olsen KM. The use of selegiline in Alzheimer's patients with behavior problems. J Clin Psychiatry 1991;52:342-345.

53.  Grimsby J, Chen K, Wang LJ, Lan NC, Shih JC. Human monoamine oxidase A and B genes exhibit identical exon-intron organization. Proc Natl Acad Sci USA 1991;88:3637-3641.

54.  Grimsby J, Lan NC, Neve R, Chen K, Shih JC. Tissue distribution of human monoamine oxidase A and B mRNA. J Neurochem 1990;55:1166-1169.

55.  Grimsby J, Toth M, Karoum F, et al. Increased stress response and beta-phenylethylamine in MAO-B-deficient mice. Nat Genet 1997;17:206-210.

56.  Grimsby J, Zentner M, Shih JC. Identification of a region important for human monoamine oxidase B substrate and inhibitor selectivity. Life Sci 1996;58:777-787.

57.  Guelfi JD, Payan C, Fermanian J, Pedarriosse AM, Manfredi R. Moclobemide versus clomipramine in endogenous depression. A double-blind randomised clinical trial. Br J Psychiatry 1992;160:519-524.

58.  Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, eds. The pharmacological basis of therapeutics, 9th edition. New York: McGraw-Hill, 1996.

59.  Hauptmann N, Grimsby J, Shih JC, Cadenas E. The metabolism of tyramine by monoamine oxidase A/B causes oxidative damage to mitochondrial DNA. Arch Biochem Biophys 1996;335:295-304.

60.  Heikkila RE, Manzino L, Cabbat FS, Duvoisin RC. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 1984;311:467-469.

61.  Hirata M, Magata Y, Ohmomo Y, et al. Evaluation of radioiodinated iodoclorgyline as a SPECT radiopharmaceutical for MAO-A in the brain. Nucl Med Biol 1995;22:175-180.

62.  Hotamisligil GS, Girmen AS, Fink JS, et al. Hereditary variations in monoamine oxidase as a risk factor for Parkinson's disease. Movement Disord 1994;9:305-310.

63.  Houlihan DJ, Gershon S. Role of monoamine oxidase inhibitors in psychiatry. In: Lieberman A, Olanow CW, Youdim MBH, Tipton K, eds. Monoamine oxidase inhibitors in neurological diseases. New York: Marcel Dekker, Inc., 1994;295-351.

64.  Hsiao JK, Potter WZ. Mechanisms of action of antipanic drugs. In: Ballenger JC, ed. Clinical aspects of panic disorder. New York: Wiley-Liss, 1990;297-317.

65.  Jahng JW, Houpt TA, Wessel TC, Chen K, Shih JC, Joh TH. Localization of monoamine oxidase A and B mRNA in the rat brain by in situ hybridization. Synapse 1997;25:30-36.

66.  Jermain DM, Hughes PL, Follender AB. Potential fluoxetine-selegiline interaction. Ann Pharmacother 1992;26:1300.

67.  Johnston JP. Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol 1968;17:1285-1297.

68.  Jossan SS, Gillberg PG, Gottfries CG, Karlsson I, Oreland L. Monoamine oxidase B in brains from patients with Alzheimer's disease: a biochemical and autoradiographical study. Neuroscience 1991;45:1-12.

69.  Kalaria RN, Harik SI. Blood-brain barrier monoamine oxidase: enzyme characterization in cerebral microvessels and other tissues from six mammalian species, including human. J Neurochem 1987;49:856-864.

70.  Karoum F, Chuang LW, Eisler T, et al. Metabolism of (-) deprenyl to amphetamine and methamphetamine may be responsible for deprenyl's therapeutic benefit: a biochemical assessment. Neurology 1982;32:503-509.

71.  Kayser A, Robinson DS, Yingling K, Howard DB, Corcella J, Laux D. The influence of panic attacks on response to phenelzine and amitriptyline in depressed outpatients. J Clin Psychopharmacol 1988;8:246-253.

72.  Kitahama K, Denney RM, Maeda T, Jouvet M. Distribution of type B monoamine oxidase immunoreactivity in the cat brain with reference to enzyme histochemistry. Neuroscience 1991;44:185-204.

73.  Knoll J. Extension of life span of rats by long-term (-)deprenyl treatment. Mt Sinai J Med 1988;55:67-74.

74.  Konradi C, Kornhuber J, Froelich L, et al. Demonstration of monoamine oxidase-A and -B in the human brainstem by a histochemical technique. Neuroscience 1989;33:383-400.

75.  Kornhuber J, Konradi C, Mack-Burkhardt F, Riederer P, Heinsen H, Beckmann H. Ontogenesis of monoamine oxidase-A and -B in the human brain frontal cortex. Brain Res 1989;499:81-86.

76.  Koshikawa N, Durcan MJ, Dunn G, Campbell IC. Circadian studies of 5HT2 receptors: effects of clorgyline administration. Pharmacol Biochem Behav 1988;30:347-350.

77.  Kumlien E, Bergstrom M, Lilja A, et al. Positron emission tomography with [11C]deuterium-deprenyl in temporal lobe epilepsy. Epilepsia 1995;36:712-721.

78.  Lan NC, Chen CH, Shih JC. Expression of functional human monoamine oxidase A and B cDNAs in mammalian cells. J Neurochem 1989;52:1652-1654.

79.  Lan NC, Heinzmann C, Gal A, et al. Human monoamine oxidase A and B genes map to Xp 11.23 and are deleted in a patient with Norrie disease. Genomics 1989;4:552-559.

80.  Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983;219:979-980.

81.  Laux G, Classen W, Sofic E, et al. Clinical, biochemical and psychometric findings with the new MAO-A-inhibitors moclobemide and brofaromine in patients with major depressive disorder. J Neural Transm Suppl 1990;32:189-195.

82.  Levitt P, Pintar JE, Breakefield XO. Immunocytochemical demonstration of monoamine oxidase B in brain astrocytes and serotonergic neurons. Proc Natl Acad Sci USA 1982;79:6385-6389.

83.  Lewinsohn R, Glover V, Sandler M. Development of benzylamine oxidase and monoamine oxidase A and B in man. Biochem Pharmacol 1980;29:1221-1230.

84.  Lewinsohn R, Glover V, Sandler M. b-phenylethylamine and benzylamine as substrates for human monoamine oxidase A: A source of some anomalies? Biochem Pharmacol 1980;29:777-781.

85.  Liebowitz MR, Quitkin FM, Stewart JW, et al. Antidepressant specificity in atypical depression. Arch Gen Psychiatry 1988;45:129-137.

86.  Liebowitz MR, Schneier F, Campeas R, et al. Phenelzine vs atenolol in social phobia. A placebo-controlled comparison. Arch Gen Psychiatry 1992;49:290-300.

87.  Mangoni A, Grassi MP, Frattola L, et al. Effects of a MAO-B inhibitor in the treatment of Alzheimer disease. Eur Neurol 1991;31:100-107.

88.  Mann JJ, Aarons SF, Wilner PJ, et al. A controlled study of the antidepressant efficacy and side effects of (-)-deprenyl. A selective monoamine oxidase inhibitor. Arch Gen Psychiatry 1989;46:45-50.

89.  Mann JJ, Kaplan RD, Bird ED. Elevated postmortem monoamine oxidase B activity in the caudate nucleus in Huntington's disease compared to schizophrenics and controls. J Neural Transm 1986;65:277-283.

90.  McGrath PJ, Stewart JW, Harrison W, Quitkin FM. Treatment of tricyclic refractory depression with a monoamine oxidase inhibitor antidepressant. Psychopharmacol Bull 1987;23:169-172.

91.  Merikangas KR, Merikangas JR. Combination monoamine oxidase inhibitor and beta-blocker treatment of migraine, with anxiety and depression. Biol Psychiatry 1995;38:603-610.

92.  Monteverde A, Gnemmi P, Rossi F, Monteverde A, Finali GC. Selegiline in the treatment of mild to moderate Alzheimer-type dementia. Clin Ther 1990;12:315-322.

93.  Murphy DL, Aulakh CS, Garrick NA, et al. Monoamine oxidase inhibitors as antidepressants: Implications for the mechanism of action of antidepressants and the psychobiology of affective disorders and some related disorders. In: Meltzer H, ed. Psychopharmacology: The third generation of progress. New York: Raven Press, 1987;545-552.

94.  Myllylä VV, Sotaniemi K, Mäki-Ikola O, Rinne UK, Heinonen EH. Role of selegiline in combination therapy of Parkinson's disease. Neurology 1996;47(Suppl 3):S200-S209.

95.  Nair NP, Ahmed SK, Kin NM, West TE. Reversible and selective inhibitors of monoamine oxidase A in the treatment of depressed elderly patients. Acta Psychiatr Scand Suppl 1995;386:28-35.

96.  Neuvonen PJ, Pohjola-Sintonen S, Tacke U, Vuori E. Five fatal cases of serotonin syndrome after moclobemide-citalopram or moclobemide-clomipramine overdoses. Lancet 1993;342:1419.

97.  Nolen WA, van de Putte JJ, Dijken WA, et al. Treatment strategy in depression. II. MAO inhibitors in depression resistant to cyclic antidepressants: two controlled crossover studies with tranylcypromine versus L-5-hydroxytryptophan and nomifensine. Acta Psychiatr Scand 1988;78:676-683.

98.  Nutt DJ, Glue P, Lawson C. The neurochemistry of anxiety: an update. Prog Neuropsychopharmacol Biol Psychiatry 1990;14:737-752.

99.  O'Carroll AM, Fowler CJ, Phillips JP, Tobbia I, Tipton KF. The deamination of dopamine by human brain monoamine oxidase. Specificity for the two enzyme forms in seven brain regions. Naunyn-Schmiedebergs Arch Pharmacol 1983;322:198-202.

100.  Oreland L. Monoamine oxidase in neuropsychiatric disorders. In: Yasuhara H, Parvez SH, Sandler M, Oguchi K, Nagatsu T, eds. Monoamine oxidase: Basic and clinical aspects. Utrecht: VSP Press, 1993;219-247.

101.  Oreland L, Arai Y, Stenström A. Age, neuropsychiatric diseases and brain monoamine oxidase. In: Tipton KF, Dostert P, Strolin-Benedetti M, eds. Monoamine oxidase and disease. London: Academic Press, 1984;291-300.

102.  Oreland L, Hallman J. The correlation between platelet MAO activity and personality: Short review of findings and a discussion on possible mechanisms. In: Yu PM, Tipton KF, Boulton AA, eds. Progress in brain research. XXX: Elsevier Science BV, 1995;77-84.

103.  Parkinson GS. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1989;321:1364-1371.

104.  Parkinson GS. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993;328:176-183.

105.  Parkinson GS. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. Ann Neurol 1996;39:29-36.

106.  Parsons B, Quitkin FM, McGrath PJ, et al. Phenelzine, imipramine, and placebo in borderline patients meeting criteria for atypical depression. Psychopharmacol Bull 1989;25:524-534.

107.  Poirier MF, Loo H, Dennis T, Le Fur G, Scatton B. Platelet monoamine oxidase activity and plasma 3,4-dihydroxyphenylethylene glycol levels during the menstrual cycle. Neuropsychobiol 1985;14:165-169.

108.  Quitkin FM, McGrath PJ, Stewart JW, et al. Atypical depression, panic attacks, and response to imipramine and phenelzine. A replication. Arch Gen Psychiatry 1990;47:935-941.

109.  Ramaekers JG, van Veggel LM, O'Hanlon JF. A cross-study comparison of the effects of moclobemide and brofaromine on actual driving performance and estimated sleep. Clin Neuropharmacol 1994;17(Suppl 1):S9-18.

110.  Ramsay RR, Krueger MJ, Youngster SK, Gluck MR, Casida JE, Singer TP. Interaction of 1-methyl-4-phenylpyridinium ion (MPP+) and its analogs with the rotenone/piericidin binding site of NADH dehydrogenase. J Neurochem 1991;56:1184-1190.

111.  Razani J, White KL, White J, et al. The safety and efficacy of combined amitriptyline and tranylcypromine antidepressant treatment. A controlled trial. Arch Gen Psychiatry 1983;40:657-661.

112.  Riederer P, Sofic E, Rausch WD, et al. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem 1989;52:515-520.

113.  Rinne JO, Roytta M, Paljarvi L, Rummukainen J, Rinne UK. Selegiline (deprenyl) treatment and death of nigral neurons in Parkinson's disease. Neurology 1991;41:859-861.

114.  Robinson DS, Lerfald SC, Bennett B, et al. Continuation and maintenance treatment of major depression with the monoamine oxidase inhibitor phenelzine: a double-blind placebo-controlled discontinuation study. Psychopharmacol Bull 1991;27:31-39.

115.  Robinson DS, Nies A, Ravaris CL, Ives JO, Bartlett D. Clinical pharmacology of phenelzine. Arch Gen Psychiatry 1978;35:629-635.

116.  Roth M, Mountjoy CQ, Amrein R. Moclobemide in elderly patients with cognitive decline and depression: an international double-blind, placebo-controlled trial. Br J Psychiatry 1996;168:149-157.

117.  Saggu H, Cooksey J, Dexter D, et al. A selective increase in particulate superoxide dismutase activity in parkinsonian substantia nigra. J Neurochem 1989;53:692-697.

118.  Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. N Engl J Med 1997;336:1216-1222.

119.  Saura J, Kettler R, Da Prada M, Richards JG. Quantitative enzyme radioautography with 3H-Ro 41-1049 and 3H-Ro 19-6327 in vitro: localization and abundance of MAO-A and MAO-B in rat CNS, peripheral organs, and human brain. J Neurosci 1992;12:1977-1999.

120.  Saura J, Luque JM, Cesura AM, et al. Increased monoamine oxidase B activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography. Neuroscience 1994;62:15-30.

121.  Schneider G, Oepen H, von Wedel HR. Monoamine oxidase activity in brain regions and organs of patients with Parkinson's disease and Huntington's disease and serum MAO activity of patients with Huntington's disease as compared with neurologically healthy individuals. Arch Psychiatr Nervenkrank 1981;230:5-15.

122.  Schneider LS, Pollock VE, Zemansky MF, Gleason RP, Palmer R, Sloane RB. A pilot study of low-dose L-deprenyl in Alzheimer's disease. J Geriatr Psychiatr Neurol 1991;4:143-148.

123.  Schulzer M, Mak E, Calne DB. The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic. Ann Neurol 1992;32:795-798.

124.  Sheehan DV, Ballenger J, Jacobsen G. Treatment of endogenous anxiety with phobic, hysterical, and hypochondriacal symptoms. Arch Gen Psychiatry 1980;37:51-59.

125.  Sheehy LM, Maxmen JS. Phenelzine-induced psychosis. Am J Psychiatry 1978;135:1422-1423.

126.  Shih JC. Molecular basis of human MAO A and B. Neuropsychopharmacol 1991;4:1-7.

127.  Shulman KI, Walker SE, MacKenzie S, Knowles S. Dietary restriction, tyramine, and the use of monoamine oxidase inhibitors. J Clin Psychopharmacol 1989;9:397-402.

128.  Sket D, Pavlin R. Monoamine oxidase in single nerve cell bodies from locus coeruleus of the rat. A microgasometric study. Biochem Pharmacol 1985;34:1025-1028.

129.  Sofic E, Paulus W, Jellinger K, Riederer P, Youdim MB. Selective increase of iron in substantia nigra zona compacta of parkinsonian brains. J Neurochem 1991;56:978-982.

130.  Spigset O, Mjorndal T, Lovheim O. Serotonin syndrome caused by a moclobemide-clomipramine interaction. BMJ 1993;306:248.

131.  Sporer KA. The serotonin syndrome. Implicated drugs, pathophysiology and management. Drug Safety 1995;13:94-104.

132.  Stabl M, Kasas A, Blajev B, et al. A double-blind comparison of moclobemide and thioridazine versus moclobemide and placebo in the treatment of refractory, severe depression. J Clin Psychopharmacol 1995;15:41S-45S.

133.  Sternbach H. The serotonin syndrome. Am J Psychiatry 1991;148:705-713.

134.  Suchowersky O, deVries JD. Interaction of fluoxetine and selegiline. Can J Psychiatry 1990;35:571-572.

135.  Targum SD, Marshall LE. Fenfluramine provocation of anxiety in patients with panic disorder. Psychiatry Res 1989;28:295-306.

136.  Tariot PN, Sunderland T, Weingartner H, et al. Cognitive effects of L-deprenyl in Alzheimer's disease. Psychopharmacology 1987;91:489-495.

137.  Tatton WG, Chalmers-Redman RME. Modulation of gene expression rather than monoamine oxidase inhibition: (-)-Deprenyl-related compounds in controlling neurodegeneration. Neurology 1996;47(Suppl 3):S171-S183.

138.  Tetrud JW, Langston JW. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science 1989;245:519-522.

139.  Trott GE, Friese HJ, Menzel M, Nissen G. Use of moclobemide in children with attention deficit hyperactivity disorder. Psychopharmacology 1992;106(Suppl):S134-S136.

140.  Tsang D, Ho KP, Wen HL. Ontogenesis of multiple forms of monoamine oxidase in rat brain regions and liver. Develop Neurosci 1986;8:243-250.

141.  Tyrer P. Clinical effects of abrupt withdrawal from tri-cyclic antidepressants and monoamine oxidase inhibitors after long-term treatment. J Affect Disord 1984;6:1-7.

142.  van Vliet IM, den Boer JA, Westenberg HG. Psychopharmacological treatment of social phobia: clinical and biochemical effects of brofaromine, a selective MAO-A inhibitor. Eur Neuropsychopharmacol 1992;2:21-29.

143.  van Vliet IM, Westenberg HG, Den Boer JA. MAO inhibitors in panic disorder: clinical effects of treatment with brofaromine. A double blind placebo controlled study. Psychopharmacology 1993;112:483-489.

144.  Versiani M, Gentil V, Guz J. Data about 508 cases of panic disorder and responses to treatment with alprazolam, clomipramine, imipramine and tranylcypromine. In: Shagass C, ed. Biological psychiatry. Amsterdam: Elsevier Science, 1986;689-697.

145.  Versiani M, Mundim FD, Nardi AE, Liebowitz MR. Tranylcypromine in social phobia. J Clin Psychopharmacol 1988;8:279-283.

146.  Versiani M, Nardi AE, Mundim FD, Alves AB, Liebowitz MR, Amrein R. Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine. Br J Psychiatry 1992;161:353-360.

147.  Versiani M, Oggero U, Alterwain P, et al. A double-blind comparative trial of moclobemide v. imipramine and placebo in major depressive episodes. Br J Psychiatry Suppl 1989;72-77.

148.  Vossler DG, Wyler AR, Wilkus RJ, Gardner-Walker G, Vlcek BW. Cataplexy and monoamine oxidase deficiency in Norrie disease. Neurology 1996;46:1258-1261.

149.  Waldmeier PC. Amine oxidases and their endogenous substrates (with special reference to monoamine oxidase and the brain). J Neural Transm Suppl 1987;23:55-72.

150.  Walsh BT, Gladis M, Roose SP, Stewart JW, Stetner F, Glassman AH. Phenelzine vs placebo in 50 patients with bulimia. Arch Gen Psychiatry 1988;45:471-475.

151.  Wei Q, Yeung M, Jurma OP, Andersen JK. Genetic elevation of monoamine oxidase levels in dopaminergic PC12 cells results in increased free radical damage and sensitivity to MPTP. J Neurosci Res 1996;46:666-673.

152.  Westlund KN. The distribution of monoamine oxidases A and B in normal human brain. In: Lieberman A, Olanow CW, Youdim MBH, Tipton K, eds. Monoamine oxidase inhibitors in neurological diseases. New York: Marcel Dekker, Inc., 1994;1-19.

153.  Westlund KN, Denney RM, Kochersperger LM, Rose RM, Abell CW. Distinct monoamine oxidase A and B populations in primate brain. Science 1985;230:181-183.

154.  Westlund KN, Denney RM, Rose RM, Abell CW. Localization of distinct monoamine oxidase A and monoamine oxidase B cell populations in human brainstem. Neuroscience 1988;25:439-456.

155.  Westlund KN, Krakower TJ, Kwan SW, Abell CW. Intracellular distribution of monoamine oxidase A in selected regions of rat and monkey brain and spinal cord. Brain Res 1993;612:221-230.

156.  Whitaker-Azmitia PM, Zhang X, Clarke C. Effects of gestational exposure to monoamine oxidase inhibitors in rats: preliminary behavioral and neurochemical studies. Neuropsychopharmacology 1994;11:125-132.

157.  Wiberg A, Gottfries CG, Oreland L. Low platelet monoamine oxidase activity in human alcoholics. Med Biol 1977;55:181-186.

158.  Wu HF, Chen K, Shih JC. Site-directed mutagenesis of monoamine oxidase A and B: role of cysteines. Mol Pharmacol 1993;43:888-893.

159.  Youdim MB, Aronson JK, Blau K, Green AR, Grahame-Smith DG. Tranylcypromine ('Parnate') overdose: measurement of tranylcypromine concentrations and MAO inhibitory activity and identification of amphetamines in plasma. Psychol Med 1979;9:377-382.

160.  Young WF, Jr, Laws ER, Jr, Sharbrough FW, Weinshilboum RM. Human monoamine oxidase. Lack of brain and platelet correlation. Arch Gen Psychiatry 1986;43:604-609.

161.  Yu PH, Bailey BA, Durden DA, Boulton AA. Stereospecific deuterium substitution at the alpha-carbon position of dopamine and its effect on oxidative deamination catalyzed by MAO-A and MAO-B from different tissues. Biochem Pharmacol 1986;35:1027-1036.

162.  Yu PH, Davis BA, Boulton AA, Zuo DM. Deamination of aliphatic amines by type B monoamine oxidase and semicarbazide-sensitive amine oxidase; pharmacological implications. J Neural Transm Suppl 1994;41:397-406.

163.  Zhu QS, Chen K, Shih JC. Bidirectional promoter of human monoamine oxidase A (MAO A) controlled by transcription factor Sp1. J Neurosci 1994;14:7393-7403.

164.  Zhu QS, Grimsby J, Chen K, Shih JC. Promoter organization and activity of human monoamine oxidase (MAO) A and B genes. J Neurosci 1992;12:4437-4446.

165.  Zhuang Z, Hogan M, McCauley R. The in vitro insertion of monoamine oxidase B into mitochondrial outer membranes. FEBS Lett 1988;238:185-190.

166.  Zhuang ZP, Marks B, McCauley RB. The insertion of monoamine oxidase A into the outer membrane of rat liver mitochondria. J Biol Chem 1992;267:591-596.